Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis

Overview

Journal Dermatol Ther (Heidelb)

Date 2017 Feb 3

PMID 28150108

Citations 3

Authors

Gareth J Thomas

Colin A Morton

Affiliations

Soon will be listed here.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are a chemically diverse class of drugs that target the cyclooxygenase (COX) pathway and have anti-inflammatory, analgesic, and antipyretic properties. Elevated expression of COX-2 has been associated with tumor progression in skin cancer through multiple mechanisms. We present evidence for a chemoprotective effect of NSAIDs and discuss potential mechanisms of action of COX-2 in cancer. We also discuss the challenges associated with the treatment of actinic keratosis and the factors that should be taken into consideration when selecting a treatment regimen. A range of treatments are reviewed, with an emphasis on combination therapies.

Citing Articles

New insights into the functions of Cox-2 in skin and esophageal malignancies.

Moon H, White A, Borowsky A Exp Mol Med. 2020; 52(4):538-547.

PMID: 32235869 PMC: 7210257. DOI: 10.1038/s12276-020-0412-2.

Pro- and Anti-Inflammatory Cytokine Expression Levels in Macrophages; An Approach to Develop Indazolpyridin-Methanones as a Novel Inflammation Medication.

Alagumuthu M, Srivastava V, Shah M, Arumugam S, Sonaimuthu M, Arumugam N Antiinflamm Antiallergy Agents Med Chem. 2019; 19(4):425-435.

PMID: 31878864 PMC: 7579299. DOI: 10.2174/1871523019666191226104724.

Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma.

Tampucci S, Carpi S, Digiacomo M, Polini B, Fogli S, Burgalassi S Molecules. 2019; 24(9).

PMID: 31075867 PMC: 6539072. DOI: 10.3390/molecules24091793.

References

Morton C, Szeimies R, Sidoroff A, Wennberg A, Basset-Seguin N, Calzavara-Pinton P . European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol. 2015; 25(4):296-311. DOI: 10.1684/ejd.2015.2570. View

Asgari M, Chren M, Warton E, Friedman G, White E . Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol. 2010; 146(4):388-95. PMC: 2857681. DOI: 10.1001/archdermatol.2009.374. View

Greenhough A, Smartt H, Moore A, Roberts H, Williams A, Paraskeva C . The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009; 30(3):377-86. DOI: 10.1093/carcin/bgp014. View

Rundhaug J, Mikulec C, Pavone A, Fischer S . A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 2007; 46(8):692-8. DOI: 10.1002/mc.20329. View

Cohen J . Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010; 3(6):39-44. PMC: 2921751. View

Zelenay S, van der Veen A, Bottcher J, Snelgrove K, Rogers N, Acton S . Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015; 162(6):1257-70. PMC: 4597191. DOI: 10.1016/j.cell.2015.08.015. View

Fischer S, LO H, Gordon G, Seibert K, Kelloff G, Lubet R . Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999; 25(4):231-40. View

Olsen E, Abernethy M, Callen J, Glazer S, Huntley A, McCray M . A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991; 24(5 Pt 1):738-43. DOI: 10.1016/0190-9622(91)70113-g. View

Gilbert D . Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol. 2005; 4(2):161-3. View

10.

Fecker L, Stockfleth E, Braun F, Rodust P, Schwarz C, Kohler A . Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol. 2010; 130(8):2098-109. DOI: 10.1038/jid.2010.40. View

11.

Muranushi C, Olsen C, Pandeya N, Green A . Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol. 2014; 135(4):975-983. DOI: 10.1038/jid.2014.531. View

12.

Muller-Decker K . Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev. 2011; 30(3-4):343-61. DOI: 10.1007/s10555-011-9306-z. View

13.

Glogau R . The risk of progression to invasive disease. J Am Acad Dermatol. 1999; 42(1 Pt 2):23-4. DOI: 10.1067/mjd.2000.103339. View

14.

Shao Y, Li P, Zhu S, Yue J, Ji X, Ma D . MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget. 2016; 7(12):15173-86. PMC: 4924778. DOI: 10.18632/oncotarget.7908. View

15.

Shaffelburg M . Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol. 2009; 8(1):35-9. View

16.

Tober K, Wilgus T, Kusewitt D, Thomas-Ahner J, Maruyama T, Oberyszyn T . Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol. 2006; 126(1):205-11. DOI: 10.1038/sj.jid.5700014. View

17.

Pirard D, Vereecken P, Melot C, Heenen M . Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005; 297(5):185-9. DOI: 10.1007/s00403-005-0601-9. View

18.

Johannesdottir S, Chang E, Mehnert F, Schmidt M, Braae Olesen A, Sorensen H . Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012; 118(19):4768-76. DOI: 10.1002/cncr.27406. View

19.

Yalcin U, Seckin S . The expression of p53 and COX-2 in basal cell carcinoma, squamous cell carcinoma and actinic keratosis cases. Turk Patoloji Derg. 2012; 28(2):119-27. DOI: 10.5146/tjpath.2012.01110. View

20.

Brock T, McNish R, Peters-Golden M . Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999; 274(17):11660-6. DOI: 10.1074/jbc.274.17.11660. View